Core Insights - FibroBiologics has announced positive preclinical results for FSdC, a spheroid-based therapy, showing significant improvement in intervertebral disc integrity and degeneration prevention in animal models of degenerative disc disease [1][2] Group 1: Preclinical Findings - FSdC spheroids demonstrated the highest level of intervertebral disc height recovery at 12 weeks post-treatment, outperforming 2D fibroblasts and fibroblast spheroids [5] - The study revealed an unadjusted p-value of 0.00015 for FSdC spheroids in disc height recovery, indicating exceptional statistical superiority compared to 0.036 for 2D fibroblasts and 0.068 for fibroblast spheroids [5] - FSdC spheroids maintained the highest average disc size index across all time points during the 12-week study, suggesting a breakthrough potential in regenerative therapies for degenerative disc disease [5] Group 2: Company Overview - FibroBiologics is a clinical-stage biotechnology company focused on developing therapeutics for chronic diseases using fibroblast cells and materials, holding over 270 patents [4] - The company aims to advance FSdC spheroids into clinical trials, supported by comprehensive preclinical pharmacology and efficacy assessments [3] - Degenerative disc disease is a significant cause of chronic back pain and disability, affecting millions in the U.S., highlighting the unmet needs in long-term disc preservation and regeneration [2]
FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease